Clasificación en acciones
#31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Precio por acción
$0.04443294
Última sincronización: 2026-09-24
Capitalización bursátil
$13.65M
Comercio Noxopharm Limited (NOX)
Número de acciones en circulación de Noxopharm Limited (NOX)
Número de acciones en circulación al June 2026: 290.49M
Según los últimos informes financieros y el precio de las acciones de Noxopharm Limited, el número actual de acciones en circulación es 290.49M. Al final de June 2024, la empresa tenía 292.26M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Noxopharm Limited (NOX) desde 2016 hasta 2026
Acciones en circulación al final de cada año
| Año |
Acciones en circulación |
Cambiar |
|
2026 (TTM) |
290.49M |
-0.67%
|
|
2025 |
292.47M |
0.07%
|
|
2024 |
292.26M |
0.01%
|
|
2023 |
292.24M |
0.35%
|
|
2022 |
291.22M |
10.37%
|
|
2021 |
263.85M |
90.70%
|
|
2020 |
138.36M |
0.15%
|
|
2019 |
138.15M |
16.06%
|
|
2018 |
119.03M |
35.93%
|
|
2017 |
87.57M |
160.94%
|
|
2016 |
33.56M |
0.00%
|
Acciones en circulación de empresas similares o competidores
| Empresa |
Acciones en circulación |
Diferencia |
País |
|
|
253.90M |
-12.60%
|
US
|
|
|
396.00M |
36.32%
|
US
|
|
|
478.91M |
64.86%
|
AU
|
|
|
62.19M |
-78.59%
|
NL
|
|
|
- |
-
|
CH
|
